Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $1.2 million.

  • Atara Biotherapeutics' Share-based Compensation fell 8092.49% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year decrease of 5469.73%. This contributed to the annual value of $27.0 million for FY2024, which is 4050.81% down from last year.
  • Atara Biotherapeutics' Share-based Compensation amounted to $1.2 million in Q3 2025, which was down 8092.49% from $2.8 million recorded in Q2 2025.
  • Over the past 5 years, Atara Biotherapeutics' Share-based Compensation peaked at $14.3 million during Q1 2022, and registered a low of $1.2 million during Q3 2025.
  • Its 4-year average for Share-based Compensation is $9.0 million, with a median of $9.9 million in 2023.
  • In the last 5 years, Atara Biotherapeutics' Share-based Compensation plummeted by 1108.59% in 2023 and then crashed by 8092.49% in 2025.
  • Atara Biotherapeutics' Share-based Compensation (Quarter) stood at $11.4 million in 2022, then dropped by 12.64% to $9.9 million in 2023, then plummeted by 41.11% to $5.8 million in 2024, then tumbled by 79.05% to $1.2 million in 2025.
  • Its Share-based Compensation stands at $1.2 million for Q3 2025, versus $2.8 million for Q2 2025 and $4.2 million for Q1 2025.